A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ)

Trial Profile

A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ)

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2016

At a glance

  • Drugs Tasimelteon (Primary) ; Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders
  • Focus Pharmacokinetics
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top